All In Biotech

Drug Trial Radar · NCT04553770

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan (DS-8201a) With or Without Anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting

Last checked: Nov 20, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

88

Planned (sponsor's estimate)

Start

Oct 9, 2020

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Jonsson Comprehensive Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Translational Research in Oncology; Daiichi Sankyo Co., Ltd.
First posted
Sep 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 expressed at low levels on cancer cells in a targeted way and delivers deruxtecan to kill them. Anastrozole works by decreasing estrogen production and suppressing the growth of tumors that need estrogen to grow. This study is evaluating how effective trastuzumab deruxtecan is at treating hormone receptor positive cancer cells that have low levels of HER2 expressed on them when given alone or in combination with anastrozole.

Conditions

  • Early-stage Breast Cancer
  • Hormone Receptor Positive Breast Carcinoma
  • Invasive Breast Cancer
  • Stage II Breast Cancer
  • Stage IIA Breast Cancer
  • Stage IIB Breast Cancer
  • Stage III Breast Cancer

Interventions

  • AnastrozoleDrug

    Given PO

  • Therapeutic Conventional SurgeryProcedure

    Undergo surgery

  • Trastuzumab DeruxtecanBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathologic complete response (pCR) rateTime frame: Baseline to surgery

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • St. Joseph Heritage Healthcare

    Fullerton, California · Recruiting

  • Cancer Blood and Specialty Clinic

    Los Alamitos, California · Recruiting

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Torrance Memorial Physician Network / Cancer Care

    Torrance, California · Recruiting

  • PIH Health

    Whittier, California · Recruiting

  • Orlando Health, Inc. d/b/a Orlando Health UF Health Center

    Orlando, Florida · Withdrawn

  • Ft. Wayne Medical Oncology and Hematology, Inc.

    Fort Wayne, Indiana · Withdrawn

  • Cancer Center of Kansas

    Wichita, Kansas · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.